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Recently, growing evidence demonstrates that recanalization of 
chronic total occlusion (CTO) lesions exerts a beneficial effect in 
terms of improvement in left ventricular function and long-term 
survival by alleviating residual/recurrent angina, and reduces the 
need for coronary artery bypass grafting.
1)2) However, it remains un-
clear whether successful recanalization of a CTO in the non-infarct-
related artery (non-IRA) could improve clinical outcomes in patients 
with acute ST-segment elevation myocardial infarction (STEMI). An-
giography before primary percutaneous coronary intervention (PCI) 
has shown that multivessel coronary artery disease (MVD) is present 
in 40% to 65% of patients with STEMI and is associated with higher 
morbidity and mortality after reperfusion therapy.
3-5) A concurrent CTO 
in a non-IRA is present in 12% to 13% of patients with STEMI.
3)5) 
In terms of primary PCI for STEMI, previous studies demonstrated 
that the effect of MVD on mortality is mainly determined by the 
presence of a CTO in a non-IRA.
4)6) The presence of CTO lesions is a 
risk factor for incomplete PCI revascularization, which may, in turn, 
increase mortality compared to complete revascularization. Tajstra 
et al.
7) described in a cohort of 1658 STEMI patients that the effect 
of MVD on mortality was primarily due to the presence of a CTO in 
a non-IRA, which was found to be a strong and independent predic-
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tor for both early mortality (within 30 days after STEMI) and late 
mortality (from 30 days to 5 years after STEMI). In contrast, MVD 
without a concurrent CTO was found only to be a relatively weak pre-
dictor for early mortality. Moreover, MVD without CTO lost its inde-
pendent predictive value for mortality after excluding patients who 
died within 30 days after STEMI. However, in the relatively short-
term follow-up period of 1 year, the majority of patients died within 
30 days.
6)
Lee et al.
8) evaluated the impact of MVD with CTO on one-year 
mortality in patients with acute myocardial infarction (MI) includ-
ing non-STEMI (about 50%). Results of this study are in line with 
those of the previous study which demonstrating that patients with 
MVD had a higher one-year mortality compared with SVD patients.
5) 
Patients with MVD were older and had a more frequent history of 
diabetes, hypertension or previous MI, and a lower left ventricular 
ejection fraction as compared to SVD patients. Therefore, the mor-
tality difference may be explained by a higher prevalence of asso-
ciated risk factors in patients with MVD. In this study, CTO lesion 
was present in 20% of patients with MVD. CTO-PCI was attempted 
in 68% patients, while successful opening was obtained in 66% of 
the attempted cases. Patients with CTO lesions were older, more 
often diabetic, and had a more unfavorable Killip class compared 
with patients without the lesion. In the 88 patients with a CTO le-
sion, there were 11 deaths, all of which were of cardiac death. How-
ever, the presence of a CTO was not a significant predictor of one-
year overall mortality and cardiac mortality of acute myocardial in-
farction (AMI) patients. This study had several limitations. First, this 
is a single-center retrospective study, and the number of patients 
was relatively small. Second, the average follow-up period was only 
1 year, whereas a more prolonged follow-up is needed to investigate 
whether such beneficial effects persist over time. Finally, the study 
population was not uniform since patients with non-STEMI were 
about 52% of study subjects.
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may be partly explained by the greater risk profile of those with CTO. 
These patients tend to suffer from diabetes and have a previous 
MI, lower left ventricular ejection fraction, lower baseline Throm-
bolysis in Myocardial Infarction (TIMI) flow grades, and cardiogenic 
shock on admission more often than patients without CTO.
4)6)9) Le-
xis et al.
10) have demonstrated that the presence of CTO in a non-IRA 
after STEMI is associated with worse reperfusion markers and larger 
enzymatic infarct size. Another explanation of the underlying me-
chanism for the increased mortality in patients with STEMI with con-
current CTO could be that in patients with CTO, PCI was less suc-
cessful. As well, a final TIMI flow grade <3 is strongly associated with 
a worse prognosis.
11) 
It was more equently present in the CTO group. Other factors that 
might contribute to adverse outcomes in patients with CTO include 
the lack of a compensation mechanism for the decrease in the left 
ventricular ejection fraction in AMI. Patients with MVD and conco-
mitant CTO have a lower residual left ventricular ejection fraction 
and experience less improvement in left ventricular systolic function, 
strongly influencing survival.
6)
Recently, Yang et al.
12) demonstrated that successful staged re-
vascularization (ranging 7-10 days) of a CTO in the non-IRA was as-
sociated with improved survival and reduced major adverse cardiac 
event in patients with acute STEMI treated with primary PCI. The pa-
thologic process in STEMI involves the entire coronary tree and can 
lead to the destabilization and rupture of multiple atherosclerotic 
plaques, resulting in a significantly increased risk of death and re-
peated ischemic events.
13) Muitivessel PCI in the prothrombotic mi-
lieu of the hyperacute phase of infarction could result in more ad-
verse thrombotic events.
14) Owing to the paucity of data regarding 
the optimal treatment of patients with STEMI and MVD, the need 
for, and timing of, subsequent revascularization of diseased non-IRA 
vessels remains controversial. Current practice guidelines in the 
acute setting recommend revascularization of diseased non-IRA 
vessels only in the presence of hemodynamic or electrical instabili-
ty.
15) Given the complexity of CTO angioplasty which requires a skill-
ed and experienced operator staged revascularization of a CTO in the 
non-IRA after STEMI seems to be a reasonable method of treatment. 
Several studies have reported beneficial effects and demonstrated 
additional increases in left ventricular function after recanalization 
of a CTO, but only in the presence of viable myocardium.
16)17) An ad-
equately powered randomized controlled trial is warranted to in-
vestigate a possible benefit of opening a CTO early after STEMI. The 
ongoing Evaluating XIENCE V and left ventricular function in PCI on 
Occlusions after STEMI (EXPLORE) trial
18) will investigate the effects 
of opening a concurrent CTO on outcomes in this high-risk subgroup 
of patients with STEMI. 
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